S.p.A. is a highly integrated biotech company focused on the identification
and development of innovative therapies targeting cancer and AIDS.
The company has grown into a leading biotechnology company by building
on its unique strengths: scientific expertise and proprietary platforms
in the field of molecular medicine.
began as a spin-off of the Gene Therapy program of the San Raffaele
Scientific Institute, which was the first to successfully conduct
a gene therapy clinical trial in Europe. The company was founded
in 1997 as a joint venture between Boehringer Mannheim (subsequently
acquired by Roche) and Science Park Raf, the managing company of
the San Raffaele Biomedical Science Park. Initially, MolMed's mission
was to supply molecular diagnostics, therapeutic reagents, services
and processes necessary for human clinical trials in the area of
cell and gene therapy according to GMP (Good Manufacturing Process)
standards. Over the first three years, MolMed successfully developed
a unique know-how and proprietary technology platform enabling it
to develop its own therapeutic products in the field of molecular
medicine. In 2001, the company initiated a new phase of growth focusing
its mission on the discovery and development of new products in
the area of molecular medicine.
At the end of 2001, MolMed acquired Genera S.p.A, the basic research
and discovery arm of Science Park Raf in gene therapy and cancer
vaccination. The merger of the two companies will combine Genera's
research skills and intellectual property in the field of cancer
gene therapy with MolMed's specific expertise in ex vivo cell handling
and its capability to develop products through clinical trials.
is developing products targeting Cancer and AIDS, diseases of high
social impact which present a high level of unmet therapeutic needs.
MolMed's therapies against cancer encompass ground-breaking treatments
such as gene therapy, therapeutic vaccination, and vascular targeting.
These therapies have the potential to innovate current cancer treatment
by targeting the basis of the disease thus guaranteeing improved
specificity and higher quality of life by considerably reducing
adverse side effects. MolMed's unique therapeutic approach against
AIDS is based on the genetic engineering of patient cells to make
them permanently resistant to the attack of the HIV virus.
This approach will help patients who are resistant to conventional
treatment and do not tolerate the toxic side effects of long-term